PIK3CA and non-small cell lung carcinoma: In non-small cell lung cancers (NSCLC), mutations in NF1, MET, and ERBB2 account for up to 13% of tumors analyzed by molecular profiling, and elevation in MAPK and PI3K activity was observed in a large proportion of cases [15].